Symbols / IRWD $3.53 -0.28% Ironwood Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
IRWD Chart
About

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Drug Manufacturers - Spe Market Cap 575.60M
Enterprise Value 959.57M Income 24.02M Sales 296.15M
Book/sh -1.61 Cash/sh 1.32 Dividend Yield —
Payout 0.00% Employees 100 IPO —
P/E 23.53 Forward P/E 2.42 PEG —
P/S 1.94 P/B -2.20 P/C —
EV/EBITDA 7.95 EV/Sales 3.24 Quick Ratio 1.08
Current Ratio 1.13 Debt/Eq — LT Debt/Eq —
EPS (ttm) 0.15 EPS next Y 1.46 EPS Growth —
Revenue Growth -47.30% Earnings 2026-05-07 ROA 19.85%
ROE — ROIC — Gross Margin 67.88%
Oper. Margin 13.73% Profit Margin 8.11% Shs Outstand 163.06M
Shs Float 125.58M Short Float 12.71% Short Ratio 4.49
Short Interest — 52W High 5.78 52W Low 0.53
Beta 0.17 Avg Volume 3.13M Volume 1.28M
Target Price $6.10 Recom None Prev Close $3.54
Price $3.53 Change -0.28%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.10
Mean price target
2. Current target
$3.53
Latest analyst target
3. DCF / Fair value
$12.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.53
Low
$3.70
High
$10.00
Mean
$6.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-26 main Citizens Market Outperform → Market Outperform $10
2026-01-05 main Wells Fargo Equal-Weight → Equal-Weight $5
2026-01-05 up Citizens Market Perform → Market Outperform $8
2025-11-11 main Wells Fargo Equal-Weight → Equal-Weight $3
2025-04-15 down Wells Fargo Overweight → Equal-Weight $1
2025-04-15 down Jefferies Buy → Hold $1
2025-04-14 main Leerink Partners Market Perform → Market Perform $1
2025-01-30 main JMP Securities Market Outperform → Market Outperform $14
2025-01-22 main Craig-Hallum Buy → Buy $8
2024-09-09 init Leerink Partners — → Market Perform $5
2024-08-09 main Wells Fargo Overweight → Overweight $12
2024-08-09 main Craig-Hallum Buy → Buy $10
2024-05-10 main Craig-Hallum Buy → Buy $14
2024-03-01 main Wells Fargo Overweight → Overweight $14
2024-02-16 main Piper Sandler Overweight → Overweight $21
2024-01-17 init Craig-Hallum — → Buy $21
2023-12-14 init Wells Fargo — → Overweight $20
2023-09-28 init JMP Securities — → Market Outperform $22
2023-05-23 main Piper Sandler Overweight → Overweight $19
2022-08-16 main Wells Fargo — → Equal-Weight $13
News
RSS: Latest IRWD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 DENNER ALEXANDER J Director — 6,730,800 $3.05 $20,530,448
2026-03-13 DENNER ALEXANDER J Director — 4,451 $0.00 $0
2026-03-10 MCCOURT THOMAS A Chief Executive Officer — 409,836 $0.00 $0
2026-03-10 SHETZLINE MICHAEL Officer — 136,612 $0.00 $0
2026-03-10 SILVER RONALD Officer — 163,934 $0.00 $0
2026-03-10 MINARDO JOHN Officer — 136,612 $0.00 $0
2026-03-10 MARTINI GREGORY S. Chief Financial Officer — 136,612 $0.00 $0
2026-03-10 GASKINS TAMMI L Officer — 136,612 $0.00 $0
2026-02-24 MCCOURT THOMAS A Chief Executive Officer — 198,283 $3.66 $739,929
2026-02-24 SHETZLINE MICHAEL Officer — 32,582 $3.66 $121,586
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
296.15
-15.72%
351.41
-20.63%
442.74
+7.83%
410.60
Operating Revenue
296.15
-15.72%
351.41
-20.63%
442.74
+7.83%
410.60
Cost Of Revenue
—
—
—
0.00
Reconciled Cost Of Revenue
—
—
—
0.00
Gross Profit
—
—
—
410.60
Operating Expense
177.39
-30.62%
255.69
-6.82%
274.40
+71.22%
160.26
Research And Development
95.14
-14.62%
111.42
-4.02%
116.08
+162.25%
44.27
Selling General And Administration
82.26
-42.99%
144.27
-8.87%
158.31
+36.48%
115.99
Total Expenses
177.39
-30.62%
255.69
-6.82%
274.40
+71.22%
160.26
Operating Income
118.76
+24.07%
95.72
-43.14%
168.34
-32.76%
250.34
Total Operating Income As Reported
98.50
+5.78%
93.12
+109.85%
-945.43
-477.66%
250.34
EBITDA
104.65
+4.40%
100.24
+110.84%
-924.87
-453.76%
261.44
Normalized EBITDA
124.91
+21.46%
102.84
-45.56%
188.88
-27.70%
261.26
Reconciled Depreciation
1.88
-6.46%
2.01
+27.68%
1.57
+11.07%
1.42
EBIT
102.77
+4.62%
98.23
+110.60%
-926.44
-456.30%
260.02
Total Unusual Items
-20.26
-681.22%
-2.59
+99.77%
-1,113.75
-612048.90%
0.18
Total Unusual Items Excluding Goodwill
-20.26
-681.22%
-2.59
+99.77%
-1,113.75
-612048.90%
0.18
Special Income Charges
-20.26
-681.22%
-2.59
+99.77%
-1,113.77
0.00
Other Special Charges
—
—
1,095.45
—
Restructuring And Mergern Acquisition
20.26
+681.22%
2.59
-85.84%
18.32
0.00
Net Income
24.02
+2629.20%
0.88
+100.09%
-1,002.24
-672.50%
175.06
Pretax Income
70.03
+7.40%
65.20
+106.88%
-948.07
-475.59%
252.42
Net Non Operating Interest Income Expense
-28.67
-0.36%
-28.57
-974.72%
-2.66
-239.67%
1.90
Interest Expense Non Operating
32.75
-0.87%
33.03
+52.73%
21.63
+184.67%
7.60
Net Interest Income
-28.67
-0.36%
-28.57
-974.72%
-2.66
-239.67%
1.90
Interest Expense
32.75
-0.87%
33.03
+52.73%
21.63
+184.67%
7.60
Interest Income Non Operating
4.08
-8.77%
4.47
-76.45%
18.97
+99.67%
9.50
Interest Income
4.08
-8.77%
4.47
-76.45%
18.97
+99.67%
9.50
Other Income Expense
-20.06
-927.34%
-1.95
+99.82%
-1,113.75
-612048.90%
0.18
Other Non Operating Income Expenses
0.19
-69.84%
0.64
—
—
Gain On Sale Of Security
—
—
0.02
-89.56%
0.18
Tax Provision
46.01
-28.47%
64.32
-22.96%
83.49
+7.93%
77.36
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
-31.48%
0.00
Tax Effect Of Unusual Items
-4.25
-681.22%
-0.54
+99.77%
-233.89
-419435.89%
0.06
Net Income Including Noncontrolling Interests
24.02
+2629.20%
0.88
+100.09%
-1,031.56
-689.24%
175.06
Net Income From Continuing Operation Net Minority Interest
24.02
+2629.20%
0.88
+100.09%
-1,002.24
-672.50%
175.06
Net Income From Continuing And Discontinued Operation
24.02
+2629.20%
0.88
+100.09%
-1,002.24
-672.50%
175.06
Net Income Continuous Operations
24.02
+2629.20%
0.88
+100.09%
-1,031.56
-689.24%
175.06
Net Income Discontinuous Operations
—
—
—
—
Minority Interests
—
0.00
-100.00%
29.32
0.00
Normalized Income
40.02
+1266.58%
2.93
+102.39%
-122.38
-169.96%
174.94
Net Income Common Stockholders
24.02
+2629.20%
0.88
+100.09%
-1,002.24
-672.50%
175.06
Diluted EPS
0.15
+1400.00%
0.01
+100.16%
-6.45
-771.88%
0.96
Basic EPS
0.15
+1400.00%
0.01
+100.16%
-6.45
-670.80%
1.13
Basic Average Shares
161.84
+1.73%
159.08
+2.35%
155.44
+0.69%
154.37
Diluted Average Shares
162.98
+1.81%
160.08
+2.99%
155.44
-16.57%
186.31
Diluted NI Availto Com Stockholders
24.02
+2629.20%
0.88
+100.09%
-1,002.24
-658.31%
179.51
Average Dilution Earnings
—
0.00
0.00
-100.00%
4.45
Line Item Trend 2023-12-31
Total Assets
471.07
Current Assets
233.29
Cash Cash Equivalents And Short Term Investments
92.15
Cash And Cash Equivalents
92.15
Receivables
129.12
Accounts Receivable
129.12
Prepaid Assets
—
Restricted Cash
0.00
Hedging Assets Current
—
Other Current Assets
12.01
Total Non Current Assets
237.78
Net PPE
18.17
Gross PPE
27.06
Accumulated Depreciation
-8.89
Properties
0.00
Machinery Furniture Equipment
5.74
Other Properties
13.91
Leases
7.41
Goodwill And Other Intangible Assets
3.68
Other Intangible Assets
3.68
Non Current Accounts Receivable
—
Non Current Deferred Assets
212.32
Non Current Deferred Taxes Assets
212.32
Other Non Current Assets
3.61
Total Liabilities Net Minority Interest
817.37
Current Liabilities
276.10
Payables And Accrued Expenses
44.66
Payables
9.07
Accounts Payable
7.83
Current Accrued Expenses
35.59
Pensionand Other Post Retirement Benefit Plans Current
19.94
Total Tax Payable
1.24
Current Debt And Capital Lease Obligation
202.69
Current Debt
199.56
Other Current Borrowings
199.56
Current Capital Lease Obligation
3.13
Current Deferred Liabilities
2.62
Current Deferred Revenue
2.62
Other Current Liabilities
6.20
Total Non Current Liabilities Net Minority Interest
541.27
Long Term Debt And Capital Lease Obligation
512.85
Long Term Debt
498.31
Long Term Capital Lease Obligation
14.54
Other Non Current Liabilities
28.41
Stockholders Equity
-346.30
Common Stock Equity
-346.30
Capital Stock
0.16
Common Stock
0.16
Preferred Stock
0.00
Share Issued
156.35
Ordinary Shares Number
156.35
Treasury Shares Number
0.00
Additional Paid In Capital
1,355.19
Retained Earnings
-1,698.62
Gains Losses Not Affecting Retained Earnings
-3.03
Minority Interest
0.00
Other Equity Adjustments
-3.03
Total Equity Gross Minority Interest
-346.30
Total Capitalization
152.01
Working Capital
-42.81
Invested Capital
351.57
Total Debt
715.54
Net Debt
605.72
Capital Lease Obligations
17.67
Net Tangible Assets
-349.98
Tangible Book Value
-349.98
Interest Payable
5.95
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
127.04
+22.69%
103.55
-43.55%
183.43
-33.00%
273.76
Cash Flow From Continuing Operating Activities
127.04
+22.69%
103.55
-43.55%
183.43
-33.00%
273.76
Cash From Discontinued Operating Activities
—
—
—
—
Net Income From Continuing Operations
24.02
+2629.20%
0.88
+100.09%
-1,031.56
-689.24%
175.06
Depreciation Amortization Depletion
1.88
-6.46%
2.01
+27.68%
1.57
+11.07%
1.42
Depreciation
—
—
1.20
-15.37%
1.42
Amortization Cash Flow
—
—
0.40
—
Depreciation And Amortization
1.88
-6.46%
2.01
+27.68%
1.57
+11.07%
1.42
Amortization Of Intangibles
—
—
0.40
—
Other Non Cash Items
1.67
-12.39%
1.90
-99.83%
1,097.51
+59128.76%
1.85
Stock Based Compensation
17.25
-42.21%
29.85
-6.73%
32.01
+18.33%
27.05
Deferred Tax
40.80
-40.08%
68.09
-6.26%
72.64
+10.49%
65.74
Deferred Income Tax
40.80
-40.08%
68.09
-6.26%
72.64
+10.49%
65.74
Operating Gains Losses
0.09
+18.67%
0.07
+494.74%
-0.02
+89.44%
-0.18
Gain Loss On Investment Securities
—
—
-0.02
+89.56%
-0.18
Gain Loss On Sale Of PPE
0.09
+18.67%
0.07
0.00
-100.00%
0.00
Change In Working Capital
41.34
+5493.78%
0.74
-93.45%
11.28
+299.96%
2.82
Change In Receivables
35.15
-25.59%
47.24
+5012.12%
0.92
-88.44%
7.99
Changes In Account Receivables
35.15
-25.59%
47.24
+5012.12%
0.92
-88.44%
7.99
Change In Inventory
—
—
—
0.00
Change In Prepaid Assets
0.37
+312.36%
0.09
-97.89%
4.22
+30.89%
3.22
Change In Payables And Accrued Expense
2.10
+106.01%
-34.86
-635.86%
6.50
+134.69%
-18.75
Change In Accrued Expense
-4.11
+71.97%
-14.65
-149.36%
-5.88
+44.77%
-10.64
Change In Payable
6.20
+130.69%
-20.21
-263.23%
12.38
+252.54%
-8.12
Change In Account Payable
6.20
+130.69%
-20.21
-263.23%
12.38
+252.54%
-8.12
Change In Other Current Assets
2.13
+203.27%
0.70
-37.03%
1.12
-24.46%
1.48
Change In Other Current Liabilities
1.59
+112.81%
-12.43
-735.48%
-1.49
-116.76%
8.88
Investing Cash Flow
-0.03
+76.06%
-0.14
+99.99%
-1,026.32
-754545.59%
-0.14
Cash Flow From Continuing Investing Activities
-0.03
+76.06%
-0.14
+99.99%
-1,026.32
-754545.59%
-0.14
Cash From Discontinued Investing Activities
—
—
—
—
Net PPE Purchase And Sale
-0.03
+76.06%
-0.14
+47.99%
-0.27
-100.74%
-0.14
Purchase Of PPE
-0.03
+76.06%
-0.14
+47.99%
-0.27
-100.74%
-0.14
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.03
+76.06%
-0.14
+47.99%
-0.27
-100.74%
-0.14
Net Business Purchase And Sale
—
0.00
+100.00%
-1,026.05
0.00
Purchase Of Business
—
0.00
+100.00%
-1,026.05
0.00
Financing Cash Flow
0.22
+100.20%
-106.97
-138.60%
277.16
+216.67%
-237.55
Cash Flow From Continuing Financing Activities
0.22
+100.20%
-106.97
-138.60%
277.16
+216.67%
-237.55
Net Issuance Payments Of Debt
0.00
+100.00%
-115.00
-138.33%
300.00
+348.55%
-120.70
Issuance Of Debt
0.00
-100.00%
150.00
-62.50%
400.00
0.00
Repayment Of Debt
0.00
+100.00%
-265.00
-165.00%
-100.00
+17.15%
-120.70
Long Term Debt Issuance
0.00
-100.00%
150.00
-62.50%
400.00
0.00
Long Term Debt Payments
0.00
+100.00%
-265.00
-165.00%
-100.00
+17.15%
-120.70
Net Long Term Debt Issuance
0.00
+100.00%
-115.00
-138.33%
300.00
+348.55%
-120.70
Net Common Stock Issuance
—
0.00
0.00
+100.00%
-126.39
Common Stock Payments
—
0.00
0.00
+100.00%
-126.39
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-126.39
Proceeds From Stock Option Exercised
0.22
-98.04%
11.01
+73.24%
6.36
-33.36%
9.54
Net Other Financing Charges
—
-2.98
+89.78%
-29.20
—
Changes In Cash
127.23
+3670.75%
-3.56
+99.37%
-565.73
-1668.25%
36.07
Effect Of Exchange Rate Changes
-0.33
-928.13%
-0.03
+39.62%
-0.05
0.00
Beginning Cash Position
88.56
-3.90%
92.15
-85.99%
657.94
+5.80%
621.86
End Cash Position
215.46
+143.29%
88.56
-3.90%
92.15
-85.99%
657.94
Free Cash Flow
127.01
+22.83%
103.41
-43.54%
183.15
-33.06%
273.63
Interest Paid Supplemental Data
30.33
-6.85%
32.56
+140.28%
13.55
+135.89%
5.75
Income Tax Paid Supplemental Data
3.54
-57.86%
8.41
-15.46%
9.95
+115.49%
4.62
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category